摘要目的 分析未见原核(0PN)来源胚胎和正常受精的双原核(2PN)来源胚胎的优质囊胚形成率,以及囊胚冻融移植后的临床结局,评价0PN囊胚的临床应用价值及新生儿情况.方法 回顾性分析2015年1月—2016年12月在山东大学附属生殖医院体外受精(IVF)或卵母细胞胞质内单精子注射(ICSI)治疗周期中出现的0PN来源胚胎及2PN来源胚胎的临床资料,分析两种受精方式0PN来源胚胎及2PN来源胚胎的优质囊胚形成率;收集囊胚冻融移植周期中,移植IVF或ICSI来源的、第5天(D5)或第6天(D6)2PN囊胚及0PN囊胚的临床资料,分析临床妊娠率、胚胎种植率、流产率、活产率和新生儿异常率.结果(1)IVF方案中2PN来源胚胎比0PN来源胚胎的优质囊胚形成率略高(分别为46.64%、42.42%),差异有统计学意义(P<0.01);ICSI方案中2PN来源胚胎的优质囊胚形成率(41.96%)更显著高于0PN来源胚胎(21.73%),差异也有统计学意义(P<0.01).(2)囊胚冻融移植周期中,IVF方案的D5 0PN囊胚的临床妊娠率、胚胎种植率、流产率、活产率和新生儿异常率(分别为52.64%、49.91%、17.37%、46.54%、1.31%),分别与D6 2PN囊胚的临床妊娠率、胚胎种植率、流产率、活产率和新生儿异常率(分别为46.78%、41.20%、23.36%、39.56%、4.21%)比较,差异均有统计学意义(P均<0.05).IVF方案的D5 2PN囊胚的临床妊娠率、胚胎种植率、活产率和新生儿异常率(分别为59.73%、55.95%、53.03%、3.90%),分别与D5 0PN囊胚的相应指标比较,差异均有统计学意义(P均<0.05);其中新生儿异常率2PN囊胚略高于0PN囊胚,余3项均优于0PN囊胚;流产率无明显差异(P>0.05).IVF方案中D5 2PN囊胚的临床妊娠率、胚胎种植率、流产率和活产率(分别为59.73%、55.95%、18.23%、53.03%)与D6 2PN囊胚的相应各率(分别为46.78%、41.20%、23.36%、39.56%)分别比较,差异均有统计学意义(P均<0.05),仅新生儿异常率无明显差异(P>0.05).结论 在优先移植2PN囊胚的原则上,0PN囊胚在知情同意后可以用来移植;IVF方案中,综合2PN和0PN囊胚的发育速度和质量评价,选择获得妊娠可能性大的囊胚进行移植.

abstractsObjective To evaluate the application value of the blastocysts derived from non-pronucleus (0PN) zygotes by the good quality blastocyst formation rate and the clinical outcomes of frozen-thawed blastocyst transfers. Methods The good quality blastocyst formation rate derived from 0PN zygotes was compared with that derived from2 pronucleus(2PN)zygotes in in vitro fertilization(IVF)or intracytoplasmic sperm injection (ICSI) cycles from January 2015 to December 2016. In addition, the clinical pregnancy, embryo implantation and live birth rates of frozen-thawed blastocyst transfers with blastocysts derived from 0PN and 2PN zygotes were analyzed on corresponding dates. Results (1)In IVF cycles, the high quality blastocysts formation rate of 2PN embryos was significantly higher than that of 0PN (46.64% versus 42.42%, P<0.01). In ICSI cycles, the high quality blastocysts formation rate of 2PN embryos was markedly higher than that of 0PN(41.96% versus 21.73%, P<0.01).(2)In frozen-thawed embryo transfer cycles for IVF, the clinical pregnancy, implantation and live birth rates of D5 0PN blastocysts were significantly higher than those of D6 2PN(52.64% versus 46.78%, 49.91% versus 41.20%, 46.54% versus 39.56%, all P<0.05), however, the abortion and newborn abnormal rates of D5 0PN blastocysts were lower than those of D6 2PN blastocysts(17.37% versus 23.36%, 1.31% versus 4.21%, both P<0.05); the clinical pregnancy, implantation and livebirth rates of D5 2PN blastocysts were significantly higher than those of D5 0PN(59.73% versus 52.64%, 55.95% versus 49.91%, 53.03% versus 46.54%, all P<0.05), but newborn abnormal rate was a little higher than that of D5 0PN(3.90% versus 1.31%, P<0.05);the clinical pregnancy, implantation and live birth rates of D5 2PN blastocysts were significantly higher than those of D6 2PN(59.73% versus 46.78%, 55.95% versus 41.20%, 53.03% versus 39.56%, all P<0.05), and the abortion rate of D5 2PN blastocysts was lower than that of D6 2PN blastocysts(18.23% versus 23.36%, P<0.05). Conclusions Although the blastocysts derived from 0PN could be transffered, the blastocysts derived from 2PN zygotes are preferred in all cycles. In IVF cycles, the good quality blastocysts derived from 2PN or 0PN zygotes will be transferred.